```html

EU MDR 2017/745 · 2026 Edition

6 EU MDR Compliance Strategies for Medical Device Manufacturers

EU MDR 2017/745 compliance is not a checklist. It is a clinical evidence architecture that must be designed from protocol version 1.

These six strategies — drawn from the operational experience of former Notified Body reviewers at Eclevar MedTech — cover every major compliance lever available to device manufacturers navigating the current regulatory landscape.

Book a free regulatory check-up Explore the 6 strategies

EU
MDR
2017/745

Framework EU MDR 2017/745

Guidance MDCG 2020-13

Standard ISO 14155:2026

FRAMEWORK EU MDR 2017/745

GUIDANCE MDCG 2020-13

STANDARD ISO 14155:2026

UPDATED April 2026

01 STRATEGY 01

Build a CER that survives Notified Body scrutiny

EU MDR Art. 61 · Annex XIV Part A · MDCG 2020-13

CER services

The Clinical Evaluation Report is the single most scrutinised document in a medical device technical file. Under EU MDR 2017/745, a CER that was sufficient under MDD is rarely sufficient today.

Notified Bodies now require a validated Clinical Evaluation Plan (CEP) before the evaluation begins, a PRISMA-compliant systematic literature review, and a benefit-risk conclusion explicitly benchmarked against the state of the art for the indication.

What manufacturers consistently get wrong

The most common CER failure mode is not insufficient data — it is insufficient methodology documentation.

A CEP produced after the CER, a literature section that is a citation list rather than a systematic review, or a benefit-risk conclusion that does not reference alternative treatments are the three most frequent causes of major non-conformity findings at technical file review.

Produce and version-control the CEP before beginning any literature search
Document search strategy with database names, date ranges, and search strings
Apply a validated critical appraisal tool to every included data source
Map CER data gaps directly to PMCF Plan activities — the two documents are interdependent
For Class III devices: secure a formal access agreement before relying on equivalence

Notified Body perspective “The majority of CER deficiencies I reviewed at TUV SUD were not failures of clinical evidence — they were failures of methodology documentation.” — Dr. Nikhil Khadabadi, CMO, former TUV SUD Senior Reviewer.

02 STRATEGY 02

Design your PMCF program before CE marking, not after

Annex XIV Part B · MDCG 2020-7 · ISO 14155:2026

PMCF services

Post-Market Clinical Follow-Up is not a post-market activity — it is a compliance architecture that must be designed in parallel with the CE marking strategy.

Manufacturers who treat PMCF as an afterthought consistently discover that their post-market data collection is either insufficient for Notified Body review, or incompatible with the data gaps identified in their CER.

Annex XIV Part B: what your PMCF plan must address

The PMCF Plan must specify which PMCF activities will be conducted — surveys, clinical investigations, registry participation, literature monitoring — at what frequency, and how each activity addresses a specific unresolved data gap from the CER.

Draft the PMCF Plan in parallel with the CER — not after it
Map every CER data gap to a specific PMCF activity with timeline and methodology
For Class IIb/III: plan for 5 to 10-year long-term follow-up from day one
Include EUDAMED-compatible serious adverse event coding from the PMCF protocol design stage
Validate your PMCF survey instruments before deployment — Level 4 quality requires documented validation

Eclevar approach We co-author the CER and PMCF Plan in a single integrated workflow. Every data gap identified in the CER generates a corresponding PMCF activity commitment — no orphaned gaps, no Notified Body surprises.

03 STRATEGY 03

Deploy an EDC platform built for EU MDR — not adapted from pharma

ISO 14155:2026 · 21 CFR Part 11 · Annex XIV mapping

MILO Health EDC

Your choice of EDC platform directly determines your compliance posture. Most EDC systems on the market were built for pharmaceutical trials and require significant configuration to meet EU MDR requirements.

Configuration is not compliance — it is risk. A platform that requires manual Annex XIV field mapping, third-party audit trail modules, or post-hoc CDISC transformation is a compliance liability disguised as a software contract.

What an EU MDR-compliant EDC must deliver natively

Annex XIV Part B field mapping pre-configured — not available as a configuration add-on
Immutable, time-stamped audit trail with 21 CFR Part 11 compliance as native architecture
AI-assisted eCRF generation directly from the clinical investigation plan (CIP) and CER
Real-time query management with documented resolution workflows
CDISC CDASH and SDTM export at any study stage — no manual transformation
Registry integration layer for NJR, EPRD, Swespine, and EUDAMED data feeds

MILO Health — EU MDR-native EDC MILO Health is Eclevar MedTech's proprietary EDC platform — built natively for EU MDR from a blank page, by a team of former Notified Body reviewers and clinical data managers.

``` ```html

04 STRATEGY 04

Integrate registry data into your PMCF architecture from year one

NJR · EPRD · Swespine · EUDAMED · RWE

Registry strategy

For Class IIb and III implantable devices — particularly in orthopedics, cardiovascular, and neuromodulation — national registries are increasingly the primary data source for long-term PMCF.

Notified Bodies are now explicitly asking manufacturers how their PMCF programs connect to the NJR (UK), EPRD (Germany), Swespine (Sweden/Denmark), and EUDAMED (EU-wide).

Manufacturers without a registry strategy are relying entirely on manufacturer-controlled surveys — a position that is becoming increasingly difficult to defend at renewal.

How to build a defensible registry-based PMCF architecture

Registry participation requires early institutional engagement — not a post-market addition. Site agreements, data access protocols, and UDI linkage must be established before first patient enrollment.

Map your device class and indication to relevant national registries at the protocol design stage
Establish UDI-DI registration in EUDAMED before initiating any PMCF activity
Negotiate data access agreements with registry administrators as part of site start-up
Ensure your EDC platform can ingest, reconcile, and export registry data in CDISC format
For Class III AIMDs: 10-year follow-up architecture is expected — registry linkage is the most cost-effective approach

05 STRATEGY 05

Make audit readiness a data architecture decision, not an event

ISO 14155:2026 · 21 CFR Part 11 · MDCG 2020-7

Data management

The most expensive data management strategy is reactive data management. Manufacturers who approach audit readiness as a pre-submission activity — rather than as a structural property of the study design — consistently face critical TMF findings, delayed database lock, and costly data remediation.

Under EU MDR, the audit trail is not a post-hoc report: it is a real-time compliance record that begins at first patient in.

Structural audit readiness: what it means in practice

A structurally audit-ready data management program means: the Data Management Plan (DMP) is approved before eCRF build; the Data Validation Plan (DVP) is pre-specified; all edit checks are documented and version-controlled; query resolution workflows are traceable; and database lock follows a documented, multi-party sign-off procedure.

Complete DMP and DVP before any eCRF configuration begins
Version-control all eCRF amendments — post-build modifications without versioning are a primary inspection finding
Conduct a formal interim data quality review at 25%, 50%, and 75% enrollment
Document all data manager and biostatistician qualifications in the TMF
Use a 100% in-house data management team — outsourced pipelines introduce version control and communication risk at every handoff

The Eclevar difference Our clinical data management is 100% in-house. No external vendors, no fragmented pipelines. Data managers sit alongside project managers and medical writers — which means faster query resolution, zero handoff risk, and a single accountability chain from DMP to database lock.

06 STRATEGY 06

Treat clinical evidence as a continuous program, not a submission event

EU MDR Art. 83–86 · PMS · PSUR · Annual CER update

PMCF activities

The most fundamental shift introduced by EU MDR relative to MDD is the requirement for continuous clinical evaluation.

CE marking is not a destination — it is a maintenance obligation. Manufacturers who secured CE marking and then treated post-market compliance as a periodic reporting exercise are now discovering that their surveillance audits surface critical findings that were accumulating silently over years.

The EU MDR post-market surveillance cycle

Under Articles 83–86 of EU MDR, manufacturers must maintain a Post-Market Surveillance system that continuously feeds into the Post-Market Surveillance Report (PMSR) or Periodic Safety Update Report (PSUR), which in turn drives the annual CER update, which in turn informs the PMCF Plan revision.

This is a closed loop — not a series of independent document updates.

Establish a formal CER review decision process — even years with no update require a documented decision
Set up structured literature monitoring with defined search frequency and reporting format
Ensure PMCF PSUR timelines align with Notified Body renewal audit schedules
For Class III: PSUR annually; for Class IIb: every two years at minimum
Train your vigilance team on EU MDR SAE reporting to EUDAMED — underreporting is a critical finding pattern at surveillance audits

Key distinction The PMSR (Class I and IIa) and PSUR (Class IIb and III) are not the same document. Manufacturers upgrading from MDD-era PMS systems frequently apply the wrong reporting framework to their device class.

How Eclevar structures compliance programs

Three differentiators that change the compliance equation

Most CROs can execute compliance activities. Very few can design them from a Notified Body perspective — before the first protocol is written. Eclevar's compliance programs are structured around three institutional advantages.

01 / EXPERTISE

Notified Body reviewers on the team

Chems HACHANI (CEO) and Dr. Nikhil Khadabadi (CMO, former TUV SUD) have reviewed hundreds of technical files from the other side of the table.

Every CER, PMCF Plan, and data management architecture we design is built around what assessors look for — and what triggers findings.

02 / TECHNOLOGY

MILO Health — the only EU MDR-native EDC

Our proprietary EDC platform eliminates the configuration risk that exists in every pharma-adapted EDC.

Annex XIV mapping, 21 CFR Part 11 audit trails, AI eCRF generation, and real-time inspection readiness scoring are native architecture.

03 / GLOBAL DELIVERY

In-house CRAs in five countries

Paris, London, Tokyo, Pune, and Mauritius. In-house CRAs in France, Germany, UK, Italy, Spain, Sweden, Denmark, Japan, and Brazil.

One accountability chain from protocol to database lock, regardless of how many countries your investigation spans.

Regulatory assessment

Book a free 1-hour regulatory check-up

Our team of former Notified Body reviewers will assess your current EU MDR compliance posture across CER, PMCF, data management, and EDC — and identify the highest-risk gaps before your next Notified Body interaction.

CER and CEP methodology review
PMCF gap mapping assessment
EDC and data management audit readiness check
Notified Body submission timeline review
PMS and PSUR cycle alignment check

No commitment

Start with a focused compliance assessment.

Identify your highest-risk gaps before your next Notified Body interaction.

Book a free regulatory check-up

TRUSTED BY

Quick reference

EU MDR compliance: regulatory documents and Eclevar resources

Each strategy above has a corresponding regulatory document and an Eclevar service page. Use this table as your compliance navigation index.

Compliance area	Key regulatory document	Priority for Class III	Eclevar service
Clinical Evaluation Report (CER)	EU MDR Art. 61 · Annex XIV Part A · MDCG 2020-13	MANDATORY	CER services
PMCF Program	Annex XIV Part B · MDCG 2020-7	MANDATORY	PMCF services
EDC / eCRF Platform	ISO 14155:2026 · 21 CFR Part 11	MANDATORY	MILO Health EDC
Registry Integration	Annex XIV Part B · EUDAMED	RECOMMENDED	RWE & registry
Data Management	ISO 14155:2026 Cl. 8 · CDISC CDASH	MANDATORY	Data management
Post-Market Surveillance	EU MDR Art. 83–86 · PSUR / PMSR	ONGOING	PMCF activities
SSCP (Class III, implantables)	EU MDR Art. 32 · MDCG 2019-9 Rev.1	MANDATORY	Medical writing

Build an EU MDR compliance architecture that stands up to scrutiny.

Talk to Eclevar's regulatory experts and identify the highest-risk gaps in your current compliance posture.